Neurodegenerative Diseases

Similarly, neuroprotection strategies for ocular disorders require adequate behavioral readouts. In a clinical context, visual function is the sole determinant of successful therapy, however, many preclinical studies solely focus on molecular or cellular readouts to determine the effects of novel drug candidates. Using the Opto Motry system (Cerebral Mechanics Inc.), functional vision and contrast sensitivity can accurately be determined in both mice and rats. Utilizing this technology we have reported impaired visual function in the DBA/2J mouse model for glaucoma. Critically, the reduced visual function was correlated with elevated intraocular pressure, a clinically relevant biomarker for glaucoma. Future preclinical development must incorporate these available technologies, and focus on clinically relevant outcome parameters. For this Special Issue we have solicited original research articles, topical reviews, and clinical case reports focusing on “Novel treatment strategies for neurological and neurodegenerative diseases”. Simon Kaja, Novel Treatment Strategies for Neurological and Neurodegenerative Diseases

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on September, 2024